Tag: source

Stockholm, 23 juni 2025 – Virtune, den svenska reglerade kapitalförvaltaren för kryptotillgångar, firade den 17 juni den officiella lanseringen av sin senaste börshandlade produkt, Virtune Coinbase 50 Index ETP, med en högtidlig bell ringing-ceremoni på Deutsche Börse Xetra i Frankfurt tillsammans med Coinbase. 

Discover comprehensive insights into the global architectural coatings market with in-depth country-specific reports. Access detailed data on market shares, product segments, prices, volumes, and values. Uncover trends in water- and solvent-based technologies, paint types, applications, and more.

Stockholm, June 23, 2025 – Virtune, the Swedish regulated crypto asset manager, celebrated the official launch of its latest exchange-traded product, the Virtune Coinbase 50 Index ETP, with a ceremonial bell ringing at Deutsche Börse Xetra in Frankfurt on June 17, together with Coinbase.

Two Argentine crews complete the podium: second Erejomovich-Llanos, third Tonconogy-Ruffini

Completano il podio due equipaggi argentini: secondi Erejomovich-Llanos, terzi Tonconogy-Ruffini

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

Company Joins Elite Group of Global Startups Tackling the World’s Most Urgent Challenges